Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Executive Summary

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

You may also be interested in...



Solvay Confirms It Is Looking At Options – But For All Of Its Businesses

In an interview, Solvay Pharma CEO says the company is “taking the offensive.”

Abbott Considering Tricor/Statin Combination On Heels Of Labeling Change

Abbott is considering developing a Tricor/statin combination product, Pharmaceutical Product Group President Jeffrey Leiden said Jan. 18

505(b)(2) Patent Certifications Attach To Reference Drug, Not Drug Substance

A 505(b)(2) NDA sponsor need only certify to patents for the reference listed drug product, not all patents associated with a drug substance, FDA said in rejecting an Abbott citizen petition regarding fenofibrate Nov. 30

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel